“pharmaceutical prediction markets are a bad bet for public health”
Three Boston University health-policy researchers argue Kalshi's markets on clinical trial endpoints and FDA approvals are a bad bet for public health. Trial participants who follow the odds may drop out, seek off-label treatment, or over-report benefits, degrading the data the markets claim to publicize. Sponsors could set easier endpoints or kill longshot trials to protect share prices. Kalshi bars sponsor employees and enrollees, but the authors say stronger reporting rules would deliver the transparency without the risk.
No technical background needed
Platforms mentioned: Kalshi, Polymarket, PredictIt